{
    "id": 1400,
    "fullName": "CDK6 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CDK6 amp indicates an increased number of copies of the CDK6 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1021,
        "geneSymbol": "CDK6",
        "terms": [
            "CDK6",
            "MCPH12",
            "PLSTIRE"
        ]
    },
    "variant": "amp",
    "createDate": "08/12/2014",
    "updateDate": "02/07/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9366,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A and CDK6 amplification in culture (PMID: 22711607).",
            "molecularProfile": {
                "id": 26838,
                "profileName": "CDK6 amp CDKN2A del"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3561,
                    "pubMedId": 22711607,
                    "title": "p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22711607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19401,
            "approvalStatus": "Phase 0",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase 0 trial, Kisqali (ribociclib) demonstrated good CNS penetration and inhibited Rb1 phoaphorylation and tumor cell proliferation, resulted in a median progression-free survival of 9.7 week and an overall survival of 7.8 months in patients (n=6) with recurrent glioblastoma with intact Rb1 expression and harboring deletion of CDKN2A or amplification of CDK4 or CDK6 (PMID: 31285369; NCT02933736).",
            "molecularProfile": {
                "id": 32265,
                "profileName": "CDK6 amp RB1 pos"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16988,
                    "pubMedId": 31285369,
                    "title": "A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31285369"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1423,
            "profileName": "CDK6 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 7730,
                    "name": "CDK4/6 Inhibitor",
                    "profileName": "CDK6 amp"
                }
            ]
        },
        {
            "id": 26835,
            "profileName": "CDK6 amp CDKN2A loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26838,
            "profileName": "CDK6 amp CDKN2A del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31573,
            "profileName": "BRAF V600E CDK6 amp EGFR amp KRAS Q61K MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32265,
            "profileName": "CDK6 amp RB1 pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}